<DOC>
	<DOCNO>NCT01273662</DOCNO>
	<brief_summary>This phase II study axitinib second-line treatment advance hepatocellular carcinoma ( HCC ) . The purpose study proof-of-concept study see axitinib anti-tumor effect HCC . The primary endpoint disease stabilization last least 8 week without progression tumor-related symptom .</brief_summary>
	<brief_title>Axitinib Second-line Treatment Advanced Hepatocellular Carcinoma</brief_title>
	<detailed_description>Axitinib inhibit activity multiple angiogenesis-related signaling pathway . Promising anti-tumor activity demonstrate patient renal cell carcinoma , thyroid cancer , melanoma . The potent anti-angiogenic activity axitinib make promising agent treatment HCC . This single-arm , open-label phase II trial . Eligible patient receive axitinib , start 5 mg orally twice daily fast status , objective disease progression , development unacceptable toxicity , voluntary discontinuation . Dose titration do accord severity adverse event .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Axitinib</mesh_term>
	<criteria>Histologically diagnose HCC , OR clinically diagnose HCC Inoperable tumor ( ) applicable curative therapy . Not amenable locoregional therapy Documented progression intolerance sorafenib treatment first line therapy advance HCC At least one measurable tumor , accord RECIST version 1.1 , treat local procedure ECOG performance status 0 1 Life expectancy least 2 month ChildPugh class A liver function . Systemic therapy sorafenib firstline therapy advance HCC History HCC tumor rupture Presence brain leptomeningeal metastasis Esophageal/gastric varix active peptic ulcer consider high risk bleed History upper gastrointestinal bleeding within 1 year Major systemic disease investigator considers inappropriate participation Uncontrollable hypertension Proteinuria Current use anticipate need treatment potent CYP3A4 inhibitor , CYP3A4 CYP1A2 inducer Requirement anticoagulant therapy oral vitamin K antagonists Dementia significantly alter mental status would prohibit understanding rendering informed consent compliance requirement protocol Other severe acute chronic medical psychiatric condition , laboratory abnormality may increase risk associate study participation judgment investigator would make patient inappropriate entry study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>HCC</keyword>
</DOC>